The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set a new standard in another patient group after proving its prowess ...

Importing foreign prices into a healthcare system not designed for them risks "embracing the worst of two worlds," Ricks said of the MFN proposal.

With high drug prices remaining an ongoing concern for U.S. | A direct-to-consumer program for its drugs could bring down higher U.S. drug prices while cutting out pharmacy benefit managers.

Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said Tuesday in its quarterly report. Merck, which is facing plummeting sales ...

Moderna won't build an mRNA plant in Japan. Otsuka and Lundbeck's Rexulti suffered a setback in PTSD. Pfizer wrapped up its PD-1xVEGF deal with 3SBio.

With RFK Jr. reportedly weighing preventive services panel revamp, HIV PrEP drugmakers could be at risk: analysts ...

With its latest $50 billion U.S. manufacturing investment and record U.S. growth, is British AstraZeneca looking at itself as an American company? | AstraZeneca CEO Pascal Soriot said the company ...

Moderna, working through operating cost and R&D cuts, to sideline 10% of global workforce by year-end ...

Technology transfer is a critical step in ensuring the successful production of high-quality biologics. It requires technical expertise and cross-functional collaboration to maintain product ...